Cargando…

Case Report: Long Progression-Free Survival of Immunotherapy for Lung Adenocarcinoma With Epidermal Growth Factor Receptor Mutation

BACKGROUND: Immune checkpoint inhibitors (ICIs) have been clinically proven to be efficient in non-small cell lung cancer (NSCLC). However, it has also been found that immunotherapy is not effective for all patients. For instance, some patients with epidermal growth factor receptor (EGFR) mutation t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peng, Jianfeng, Zhao, Xianguang, Zhao, Kaikai, Meng, Xiangjiao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495127/ https://www.ncbi.nlm.nih.gov/pubmed/34631564 http://dx.doi.org/10.3389/fonc.2021.731429

Ejemplares similares

Pseudo-progression with osimertinib after definitive chemoradiation in unresectable epidermal growth factor receptor mutation positive of stage III non-small cell lung cancer: A case report
por: Ren, Fei, et al.
Publicado: (2022)

Expression of Human Epidermal Growth Factor Receptor-2 in Resected Rectal Cancer
por: Meng, Xiangjiao, et al.
Publicado: (2015)

The Potential of Radiomics Nomogram in Non-invasively Prediction of Epidermal Growth Factor Receptor Mutation Status and Subtypes in Lung Adenocarcinoma
por: Zhao, Wei, et al.
Publicado: (2020)

Mutation-Derived Long Noncoding RNA Signature Predicts Survival in Lung Adenocarcinoma
por: Yang, Longjun, et al.
Publicado: (2022)

Maintained Complete Response and Long-Term Survival in Epidermal Growth Factor Receptor Mutated Metastatic Non-Small Cell Lung Cancer with Erlotinib
por: Alkassis, Samer, et al.
Publicado: (2021)

Using combined CT-clinical radiomics models to identify epidermal growth factor receptor mutation subtypes in lung adenocarcinoma
por: Huo, Ji-wen, et al.
Publicado: (2022)

Perspective on treatment for unresectable locally advanced non-small cell lung cancer with oncogene-driven mutation: a narrative review
por: Jiang, Liyang, et al.
Publicado: (2020)

Survival Outcomes of Patients With Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis
por: Li, Ning, et al.
Publicado: (2022)

Stage IV EGFR Mutation-Negative and ALK Mutation-Negative Lung Adenocarcinoma: Long-Term Survival is Possible
por: Kedia, Shiksha, et al.
Publicado: (2015)

Estrogen Receptor β1 Expression Patterns Have Different Effects on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors’ Treatment Response in Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma
por: Zhang, Lijuan, et al.
Publicado: (2021)

Oncological Patients With Endocrine Complications After Immunotherapy With Checkpoint Inhibitors Present Longer Progression-Free and Overall Survival
por: Paschou, Stavroula A., et al.
Publicado: (2022)

Epidermal growth factor receptor mutations and brain metastases in non-small cell lung cancer
por: Zhao, Wei, et al.
Publicado: (2022)

Inconsistent clinical outcomes following afatinib treatment in NSCLC patients harboring uncommon epidermal growth factor receptor mutation
por: Dong, Wei, et al.
Publicado: (2022)

Evaluation of Progression-Free Survival and Overall Survival of Epidermal Growth Factor Receptor-Positive Metastatic Lung Adenocarcinoma Patients Treated with Erlotinib
por: Shahriari, Saeedeh, et al.
Publicado: (2022)

Long-term follow-up of a consecutive cohort validating an epidermal growth factor receptor mutation as an independent risk factor for postoperative recurrence in lung adenocarcinoma
por: Matsumura, Yuki, et al.
Publicado: (2023)

Effect of TTN Mutations on Immune Microenvironment and Efficacy of Immunotherapy in Lung Adenocarcinoma Patients
por: Wang, Zhe, et al.
Publicado: (2021)

Computed tomography-based radiomics quantification predicts epidermal growth factor receptor mutation status and efficacy of first-line targeted therapy in lung adenocarcinoma
por: Jiang, Meilin, et al.
Publicado: (2022)

Correlations Study Between (18)F-FDG PET/CT Metabolic Parameters Predicting Epidermal Growth Factor Receptor Mutation Status and Prognosis in Lung Adenocarcinoma
por: Yang, Bin, et al.
Publicado: (2019)

Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review
por: Leonetti, Alessandro, et al.
Publicado: (2021)

Delta radiomics model for the prediction of progression-free survival time in advanced non-small-cell lung cancer patients after immunotherapy
por: Xie, Dong, et al.
Publicado: (2022)

Human epidermal growth factor receptor 2 expression in women with uterine cervix adenocarcinoma from Appalachian Kentucky
por: Kunos, Charles A., et al.
Publicado: (2023)

Heparin binding epidermal growth factor–like growth factor is a prognostic marker correlated with levels of macrophages infiltrated in lung adenocarcinoma
por: Van Hiep, Nguyen, et al.
Publicado: (2022)

Machine-Learning-Derived Nomogram Based on 3D Radiomic Features and Clinical Factors Predicts Progression-Free Survival in Lung Adenocarcinoma
por: Liu, Guixue, et al.
Publicado: (2021)

Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma
por: Liu, Hua, et al.
Publicado: (2022)

Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status
por: Isaka, Tetsuya, et al.
Publicado: (2022)

Corrigendum: Heparin binding epidermal growth factor–like growth factor is a prognostic marker correlated with levels of macrophages infiltrated in lung adenocarcinoma
por: Van Hiep, Nguyen, et al.
Publicado: (2022)

Case Report: Recombinant Human Endostatin Plus Chemotherapy for Epidermal Growth Factor Receptor-Negative Miliary Lung Adenocarcinoma
por: Zhu, Jian, et al.
Publicado: (2022)

CT characteristics in pulmonary adenocarcinoma with epidermal growth factor receptor mutation
por: Zhao, Jing, et al.
Publicado: (2017)

The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non‐small cell lung cancer patients with epidermal growth factor receptor mutation
por: Ma, Lin, et al.
Publicado: (2021)

MRI radiomics predicts progression-free survival in prostate cancer
por: Jia, Yushan, et al.
Publicado: (2022)

Bronchial Washing Fluid Versus Plasma and Bronchoscopy Biopsy Samples for Detecting Epidermal Growth Factor Receptor Mutation Status in Lung Cancer
por: Zhang, Xinyu, et al.
Publicado: (2021)

New prognostic system specific for epidermal growth factor receptor-mutated lung cancer brain metastasis
por: Zhu, Li-Hua, et al.
Publicado: (2023)

The Association of the Sequence of Immunotherapy With the Survival of Unresectable Pancreatic Adenocarcinoma Patients: A Retrospective Analysis of the National Cancer Database
por: Amin, Saber, et al.
Publicado: (2020)

The Value of Predicting Human Epidermal Growth Factor Receptor 2 Status in Adenocarcinoma of the Esophagogastric Junction on CT-Based Radiomics Nomogram
por: Wang, Shuxing, et al.
Publicado: (2021)

Identification of a novel gene signature of lung adenocarcinoma based on epidermal growth factor receptor-tyrosine kinase inhibitor resistance
por: Zhou, E., et al.
Publicado: (2022)

Immunoscore Predicts Survival in Early-Stage Lung Adenocarcinoma Patients
por: Zhao, Zihuan, et al.
Publicado: (2020)

The Efficacy and Safety of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Thymosin in Advanced Non-Small Cell Lung Cancer Patients Harboring Active Epidermal Growth Factor Receptor Mutations
por: Feng, Yongdong, et al.
Publicado: (2021)

An autophagy-related four-lncRNA signature helps to predict progression-free survival of neuroblastoma patients
por: Wang, Jing, et al.
Publicado: (2022)

Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors
por: Tsai, Ming-Ju, et al.
Publicado: (2018)

Nomograms for Predicting Disease-Free Survival in Patients With Siewert Type II/III Adenocarcinoma of the Esophagogastric Junction Receiving Neoadjuvant Therapy and Radical Surgery
por: Guo, Zhenjiang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9teeasbrtgcpgsoqqksa51jhgk